Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Tudor domain-containing protein 12 (TDRD12) is a member of the tudor domain protein family and is characterized by the presence of a central helicase domain and flanking tudor domains. TDRD12 is predominantly expressed in the testis and plays a critical role in the biogenesis of secondary PIWI-interacting RNAs (piRNAs), which are essential for the silencing of transposable elements during germ cell development. In mice, TDRD12 is localized to the acrosome of spermatids and is essential for normal spermatogenesis. Mutations or deletions in TDRD12 result in male infertility due to defects in secondary piRNA production and the failure to repress retrotransposons, leading to meiotic arrest in male germ cells. TDRD12 is not considered a conventional pharmacological target, and there are currently no known drugs or approved therapeutic agents targeting this protein[1][3][4][5][6].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Tudor domain-containing protein 12 (TDRD12).